Nordic Pancreatic Cancer Trial (NorPACT) - 1

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

December 22, 2022

Study Completion Date

April 30, 2026

Conditions
Pancreatic Cancer
Interventions
DRUG

5-FU

Neoadjuvant treatment

DRUG

Oxaliplatine

Neoadjuvant treatment

DRUG

Irinotecan

Neoadjuvant treatment

PROCEDURE

Pancreatic surgery

All patients

DRUG

5-FU

Adjuvant treatment

DRUG

Oxaliplatine

Adjuvant treatment

DRUG

Irinotecan

Adjuvant treatment

Trial Locations (13)

4011

Stavanger University Hospital, Stavanger

5021

Haukeland University Hospital, Bergen

7030

St. Olav University Hospital, Trondheim

9038

Tromsø University Hospital, Stavanger

14157

Karolinska University Hospital, Huddinge

41345

Sahlgrenska University Hospital, Gothenburg

58185

Linköping University Hospital, Linköping

75185

Uppsala University Hospital, Uppsala

90737

University Hospital of Umeå, Umeå

Unknown

Odense University Hospital, Odense

Skåne University Hospital, Lund

00029

Helsinki University Hospital, Helsinki

N- 0424

Oslo University Hospital, Oslo

All Listed Sponsors
collaborator

St. Olavs Hospital

OTHER

collaborator

Haukeland University Hospital

OTHER

collaborator

University Hospital of North Norway

OTHER

collaborator

Sahlgrenska University Hospital

OTHER

collaborator

Karolinska University Hospital

OTHER

collaborator

University Hospital, Linkoeping

OTHER

collaborator

Lund University Hospital

OTHER

collaborator

Odense University Hospital

OTHER

collaborator

Helsinki University Hospital, Finland

UNKNOWN

collaborator

Norrlands University Hospital

OTHER

collaborator

Helse Stavanger HF

OTHER_GOV

lead

Oslo University Hospital

OTHER

NCT02919787 - Nordic Pancreatic Cancer Trial (NorPACT) - 1 | Biotech Hunter | Biotech Hunter